Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine with Chemoradiation in Locally Advanced Undifferentiated Nasopharyngeal Cancer
NCT00025298Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2001
- Primary completion
- Oct 2002
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of amifostine in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Incidence of grade 3 or 4 mucositis. Started Jul 2001; status: terminated.
02
Drugs
amifostine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00025298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025298.